SCHEMBL5118596

SCHEMBL5118596

CCOC(=O)c1ccc(CCSc2ccc3c(c2)C(=O)C(=O)N3Cc2ccccc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.51
PARK7 Q99497 2/20 0.47
ALDH1A1 P00352 4/20 0.47
ALDH2 P05091 3/20 0.47
ALDH3A1 P30838 3/20 0.47
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
CTRB1 P17538 1/20 0.44
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA9 Q16790 1/20 0.43
MAPT P10636 3/20 0.43
CHRM5 P08912 2/20 0.43
PTPN1 P18031 1/20 0.43
CHRM1 P11229 1/20 0.43
CES1 P23141 1/20 0.43
CASP1 P29466 1/20 0.43
CASP3 P42574 1/20 0.43
CASP4 P49662 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5118438 0.87 PARK7 (0.60) PARK7ALDH1A1ALDH2ALDH3A1MEN1
SCHEMBL5123616 0.86 PARK7 (0.44) LMNAPARK7ALDH1A1ALDH2ALDH3A1
SCHEMBL5124615 0.85 CASP3 (0.48) LMNAPARK7ALDH1A1MEN1KMT2A
SCHEMBL5124521 0.85 PARK7 (0.44) LMNAPARK7ALDH1A1ALDH2ALDH3A1
SCHEMBL5118420 0.83 PARK7 (0.43) LMNAPARK7ALDH1A1MEN1KMT2A
SCHEMBL5126043 0.83 PARK7 (0.60) LMNAPARK7ALDH1A1ALDH2ALDH3A1
SCHEMBL5110531 0.81 ALDH1A1 (0.42) LMNAPARK7ALDH1A1ALDH2ALDH3A1
SCHEMBL5117734 0.81 CES1 (0.43) LMNAPARK7ALDH1A1ALDH2ALDH3A1
SCHEMBL5114573 0.80 LMNA (0.42) LMNAMEN1KMT2AMAPTPTPN1
SCHEMBL5125074 0.79 PARK7 (0.73) PARK7ALDH1A1ALDH2ALDH3A1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080004274-A1 Novel biaromatic compounds that modulate PPAR type receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-01-03 US disclosed
EP-1828124-A1 BIAROMATIC COMPOUNDS THAT MODULATE PPAR TYPE RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS Galderma Research & Development (FR) 2007-09-05 EP disclosed
WO-2006063863-A1 BIAROMATIC COMPOUNDS THAT MODULATE PPAR TYPE RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS GALDERMA RESEARCH & DEVELOPMENT (FR) 2006-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004274-A1 Novel biaromatic compounds that modulate PPAR type receptors and cosmetic/pharmaceutical compositions comprised thereof PPARG, PPARD, PPARA LMNA 3355/4885PARK7 2430/4885ALDH1A1 420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.